Provectus Pharmaceuticals Inc. Completes Dosing of Patients in Phase 1 Melanoma Study

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT) has successfully completed dosing in the final patient enrolled in its Phase 1 study of Provecta™ for use on Stage III/IV metastatic melanoma. Provecta is the company’s proprietary drug being tested for treatment of metastatic melanoma, breast cancer and liver cancer.

Back to news